ArticleJournal of neuroinflammation2018
Imaging glial activation in patients with post-treatment Lyme disease symptoms: a pilot study using [
Article in Journal of neuroinflammation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 62 citations in OpenAlex.
- Folate Receptor Alpha Autoantibodies in Vector-Borne Disease Populations.Diseases (Basel, Switzerland) · 2026Article
- Epidemiology, diagnosis and emerging therapies for Lyme disease of the Northern Hemisphere.International journal of emergency medicine · 2026Review
- Pilot study of psilocybin in patients with post-treatment lyme disease.Scientific reports · 2026Article
- Article
- Deep learning-derived arterial input function for dynamic brain PET.NeuroImage · 2025Article
- Early brain changes in Lyme disease are associated with clinical outcomes.Brain, behavior, & immunity - health · 2025Article
- Core features and inherent diversity of post-acute infection syndromes.Frontiers in immunology · 2025Review
- Intestinal barrier compromise, viral persistence, and immune dysregulation converge on neurological sequelae in Long COVID.Frontiers in aging neuroscience · 2025Review
- Fibroblast growth factor receptor inhibitors mitigate the neuropathogenicity ofFrontiers in immunology · 2024Article
- Dysautonomia following Lyme disease: a key component of post-treatment Lyme disease syndrome?Frontiers in neurology · 2024Review
- Autocrine positive feedback of tumor necrosis factor from activated microglia proposed to be of widespread relevance in chronic neurological disease.Pharmacology research & perspectives · 2023Review
- Neuropsychiatric Lyme Disease and Vagus Nerve Stimulation.Antibiotics (Basel, Switzerland) · 2023Review
- Concussion: Beyond the Cascade.Cells · 2023Review
- Language Fluency Deficits in Post-treatment Lyme Disease Syndrome.Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists · 2023Article
- Assessment of cognitive function, structural brain changes and fatigue 6 months after treatment of neuroborreliosis.Journal of neurology · 2023Article
- Neuropsychiatric Symptoms and Tick-Borne Diseases.Current topics in behavioral neurosciences · 2023Article
- Superior efficacy of combination antibiotic therapy versus monotherapy in a mouse model of Lyme disease.Frontiers in microbiology · 2023Article
- The choroid plexus and its role in the pathogenesis of neurological infections.Fluids and barriers of the CNS · 2022Review
- Development ofACS chemical neuroscience · 2022Article
- Neuropathogenicity of non-viable Borrelia burgdorferi ex vivo.Scientific reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 4 institutions in 2 countries.
Funding
Abstract
The pathophysiology of post-treatment Lyme disease syndrome (PTLDS) may be linked to overactive immunity including aberrant activity of the brain's resident immune cells, microglia. Here we used [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.